✨ Free AI Report
Senzime AB: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Senzime AB
Company Research

Senzime AB: Business Overview, Financials & Competitive Analysis

Senzime AB scores 6/10 on the AskCyborg Cyborg Score (Solid). Emerging medtech player addressing unmet perioperative patient safety needs with proven technology, facing capital requirements for scaling distribution. Early-stage medical device company with strong market positioning in perioperative monitoring and FDA/CE clearances. Revenue growth evident (~39% YoY) but small revenue base (~$7.75M TTM) and negative EPS (-$0.09) indicate commercialization challenges.

What is Senzime AB's industry? Senzime AB (senzime.com) operates in Medical Devices - Perioperative Monitoring. AskCyborg classifies Senzime AB under Medical Devices - Perioperative Monitoring in its company registry.

Senzime is a Swedish medical device company that develops and markets CE- and FDA-cleared patient monitoring systems, including TetraGraph® and ExSpiron® 2Xi for monitoring neuromuscular and respiratory functions duri...

6/ 10Solid

Cyborg Score thesis

Emerging medtech player addressing unmet perioperative patient safety needs with proven technology, facing capital requirements...

Read the full analyst-debate transcript →
Industry Medical Devices - Perioperative Monitoring
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Senzime AB Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Senzime AB

AskCyborg analysts argue the bull and bear cases for Senzime AB across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Senzime AB OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Senzime AB Overview

Pro stress-test →

Senzime is a Swedish medical device company that develops and markets CE- and FDA-cleared patient monitoring systems, including TetraGraph® and ExSpiron® 2Xi for monitoring neuromuscular and respiratory functions during and after surgery. The company's mission is to help eliminate postoperative complications for more than 100 million patients worldwide.

Strategic Profile

Pro stress-test →

Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The company has a strategic license and connectivity agreement with Masimo to develop and market the TetraGraph Smart Cable Module that connects directly to their Root monitoring system and digital hubs for hospital integration. Senzime operates in Sweden, Germany and the USA.

Competitive Landscape

Pro stress-test →

Main competitors include Philips, IDMed, Xavant, EB Neuro, and Boston Scientific in the patient monitoring space. Senzime differentiates through specialized focus on perioperative monitoring and quantitative neuromuscular assessment, occupying a niche segment within larger medical device ecosystems.

Industry Context

Senzime AB operates in Medical Devices - Perioperative Monitoring.

Key facts

Founded: 1999 · Headquarters: Uppsala, Sweden · Employees: 58 · Revenue: $7.75M (TTM, as of Jun 2025) · Market cap: $117M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Senzime AB.

  • Portfolio focused on two core platforms (TetraGraph for neuromuscular monitoring, ExSpiron for respiratory monitoring) addressing high-incidence postoperative complications in 100M+ patient markets
  • Strategic partnerships with major medical device companies (Masimo, Fukuda Denshi, Philips) accelerate market penetration and reduce commercialization burden
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • 2025Fukuda Denshi launched HN-100 module powered by TetraGraph technology in Japan market
  • 2025Multiple US hospital wins including world-leading hospital systems and state-wide university hospital contracts
  • +2 moreTrack every material event for Senzime AB as it happens. Explore monitoring →
Get alerted when Senzime AB has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Patient Monitoring SystemsBroad perioperative monitoring portfolio with integrated platform approach→Neuromuscular MonitoringNon-invasive monitoring partner with distribution and integration advantages→Anesthesia Monitoring SolutionsLarge-cap competitor with diversified surgical monitoring offerings→

Compare Senzime AB with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Senzime AB operates in Medical Devices - Perioperative Monitoring. See how the rest of the sector scores on the Cyborg framework.

Browse Medical Devices - Perioperative Monitoring research →
NEW · MCP server

Ask your AI assistant about Senzime AB

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Senzime AB and its top competitor on Cyborg Score”
“What did Senzime AB do this quarter?”
“Is Senzime AB a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Senzime AB do?+
Senzime is a Swedish medical device company that develops and markets CE- and FDA-cleared patient monitoring systems, including TetraGraph® and ExSpiron® 2Xi for monitoring neuromuscular and respiratory functions duri...
What is Senzime AB's Cyborg Score?+
Senzime AB has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Senzime AB's main competitors?+
Named competitors include Patient Monitoring Systems, Neuromuscular Monitoring, Anesthesia Monitoring Solutions. The full competitive landscape is in the AskCyborg report.
How can I get the full Senzime AB research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Senzime AB research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Senzime AB over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.